Exosomes secreted by FNDC5-BMMSCs protect myocardial infarction by anti-inflammation and macrophage polarization via NF-κB signaling pathway and Nrf2/HO-1 Axis

Hogjuan Ning
The First Affiliated Hospital of Jinzhou Medical University

Haixu Chen
Chinese PLA General Hospital

Jingyu Deng
Air Force Medical University

Chun Xiao
PLA Rocket Force Characteristic Medical Center

Lina Shan
The First Affiliated Hospital of Jinzhou Medical University

Chao Yang
PLA Rocket Force Characteristic Medical Center

Zheng Zhang (✉ zhangzheng123456@gmail.com )
PLA Rocket Force Characteristic Medical Center https://orcid.org/0000-0001-8433-1568

Research Article

Keywords: Exosomes, Bone marrow mesenchymal stem cells (BM-MSCs), Myocardial infarction (MI), Fibronectin type III domain-containing protein 5 (FNDC5), Inflammation, Macrophage polarization

DOI: https://doi.org/10.21203/rs.3.rs-754264/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Exosomes are considered a substitute for stem cell-based therapy for myocardial infarction (MI). FNDC5, a transmembrane protein located in the cytoplasm, plays a crucial role in inflammation diseases and MI repair. Furthermore, our previous study found that FNDC5 pre-conditioning bone marrow-derived mesenchymal stem cells (BMMSCs) could secreted more exosomes, but little was known on MI repair.

Methods

Exosomes isolated from BMMSCs with or without FNDC5-OV were injected into infarcted hearts. Then, cardiomyocytes apoptosis, and inflammation responses were detected. Furthermore, exosomes were administrated to RAW264.7 macrophage with LPS treatment to investigate its effect on inflammation and macrophage polarization.

Results

Compared with MSCs-Exo, FNDC5-MSCs-Exo had superior therapeutic effects on anti-inflammation and anti-apoptosis, as well as polarizing M2 macrophage *in vivo*. Meanwhile, the *in vitro* results also showed that FNDC5-MSCs–Exo decreased pro-inflammatory secretion and increased anti-inflammatory secretion under LPS stimulation, which partly depressed NF-κB signaling pathway and upregulated Nrf2/HO-1 Axis.

Conclusions

FNDC5-BMMSCs-derived exosomes play anti-inflammation effects and promote M2 macrophage polarization via NF-κB signaling pathway and Nrf2/HO-1 Axis, which may develop a promising cell-free therapy for MI.

Background

Inflammatory responses play an important role in myocardial infarction (MI) [1]. Macrophage polarization plays an important role in post-infarction inflammation and heart repair [2]. In the early stage of post-infarction, M1 macrophages which secrete pro-inflammatory cytokines, such as tumour necrosis factor-α (TNF-α), interleukin 6 (IL-6), and interleukin 1β (IL-1β) and high express CD11b and CXCL10 [3], are recruited into infarct myocardium to be responsible for pro-inflammation responses. But, during the later phage of MI, M2 macrophages which are characterized by anti-inflammatory cytokines interleukin 10 (IL-10), with high expression of CD206 and arginase I (Arg 1) [4], are dominant and participate in anti-inflammation effect and cardiac repairment [5]. Thus, to regulate a balance between M1 and M2 macrophages is essential for MI.
Increasing evidences indicate that transplantation of bone marrow-derived mesenchymal stem cells (BMMSCs) serves as a potential therapeutic for MI by anti-inflammatory, reducing fibrosis and enhancing angiogenesis [6]. However, many clinical and animal studies have found that the poor local microenvironment and excessive inflammation responses of ischemic myocardial tissue cause early death of engrafted cells after BMMSCs administration, which limits the therapeutic efficacy of BMMSCs for MI [7, 8]. Recently, exosomes have been found to be vesicles secreted by cells, containing a variety of biological substances and mediate cell-to-cell communication, as well as participates in various pathophysiological processes such as immune regulation, injured tissue repair [9–11]. Study has shown that stem cell-derived exosomes have the effects of immune regulation, anti-inflammatory, reducing fibrosis, inhibiting oxidative stress, and enhancing angiogenesis [12], suggesting they may serve as alternatives to cell therapy of BMMSCs transplantation in MI. However, previous studies have found that exosomes derived by usual stem cells have limitations to repair myocardial tissue, pre-treatment of stem cells can enhance their protective effect on ischemic myocardium [13–15]. This suggests that optimized stem cells can enhance the protective effect of exosomes on ischemic myocardium.

FNDC5, a transmembrane protein that possesses two domains (fibronectin III and carboxy-terminal, respectively) located in the cytoplasm [16], has been proposed that this molecule plays an important role in converting the white adipose tissue to brown adipose tissue and regulating the energy expenditure [17]. Apart from this, its expression and role in various other conditions such as inflammation, cardiovascular diseases, aging and other metabolic conditions have been reported [18–20]. In addition, our previous study showed that FNDC5 pre-treatment BMMSCs improved MI repair [21]. Interestingly, we also found that BMMSCs with overexpression of FNDC5 secreted more exosomes compared ordinary BMMSCs. However, the underlying mechanism are unknown. Therefore, the present study aimed to determine whether exosomes derived from genetically modified BMMSCs overexpressing FNDC5 may improve MI repair by regulation of inflammation.

**Methods**

**Isolation, culture and treatments of BMMSCs**

BMMSCs were isolated and culture as described previously [22]. Briefly, bone marrow was flushed from the femur and tibia of adult male C57BL/6 mice (8–12 weeks of age, 20–25 g) with Fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA)-free Dulbecco's modified Eagle’s medium (DMEM) (Corning, Manassas, VA, USA). After passing through a 70-µm strainer and centrifugation at 1200 rpm for 5 mins, the cell pellet was re-suspended by DMEM supplemented with 20% FBS and incubated at 37°C in an atmosphere containing 5% CO₂ for 24 h. The medium was replaced to remove the non-adherent cells and then was completely replaced every 3 days. Third generation BMMSCs with optimal growth were applied for further treatments. Furthermore, cells were treated by FNDC5 overexpression as described previously [21].

**Exosome isolation and identification**
Cells were cultured with DMEM containing 5% exosome-depleted FBS (Thermo Fisher Scientific). Subsequently, the supernatant was collected and centrifuged at 2000g for 20 mins followed by 10,000g for 30 mins at 4°C to remove cell debris, apoptotic bodies, and microvesicles. Furthermore, the supernatant was filtered with 0.22-µm filters. Isolation of exosomes was performed with ultracentrifugation as described previously [23]. The isolated exosomes were verified by transmission electron microscopy (TEM, Hitachi H7650 TEM). Nanoparticle tracking analysis (NTA) was applied to record the concentration and size distribution of exosomes using NanoSight NS300.

**Induction of MI model and intramyocardial injection of exosomes**

Mice MI model was accomplished by ligation of the left anterior descending (LAD) artery [24]. In brief, C57BL/6 mice were anesthetized with isoflurane and mechanically ventilated. The heart was exposed between the fourth and fifth ribs by left thoracotomy. Next, LAD artery was permanently ligated using a 6−0 polyester suture. Success of the ligation was confirmed when the anterior wall of the left ventricle (LV) turned pale and characteristic electrocardiographic (ECG) changes were recorded. The mice were randomized into four groups: sham-operated group (sham), PBS group, MSCs-Exo group and FNDC5-MSCs-Exo group. Immediately after LAD ligation, exosomes suspended in PBS were injected into myocardium at four sites around the infarct border zone [25]. Mice were then sacrificed at 3 and 7 days after MI for tissue harvesting. All animal studies were undertaken in accordance with the regulations and guidelines of Institutional Animal Care and Use Committee of PLA Rocket Force Characteristic Medical Center (Beijing, China). Completely randomized design and blinding were adopted in animal experiments.

**Measurement of BM-MSC apoptosis**

Apoptotic cardiomyocytes in the infarcted heart were detected by a Terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) Assay Kit (In Situ Cell Death Detection Kit; Roche Diagnostics) according to the manufacturer's instructions and detected by confocal microscopy (Olympus Fluoview 2000).

**Enzyme-linked immunosorbent assay (ELISA)**

Mice serum and cell medium supernatants were collected and stored at −20°C for the subsequent analysis of cytokines. ELISA kits were performed in accordance with the manufacturer's instructions.

**Haematoxylin and eosin (H&E) staining**

Different treatments mice were killed at 3 and 7 days after myocardial injection. Then, the fresh heart was fixed in 4% paraformaldehyde, embedded in paraffin and sectioned at 5-µm intervals. H&E staining of heart sections were performed as described previously [26].

**The treatments of Raw264.7 cells**
Raw264.7 cells were purchased from American Type Culture Collection. Cells were co-cultured with different concentrations of exosome suspension (5, 10, 15 and 20 µg/mL) for 24 h as previously described [27]. Then, they were cultured with LPS (100 ng/mL) for another 24 h to perform further study.

**Cell counting kit-8 (CCK-8) assay**

Cell viability was detected using CCK-8 assay (Dojindo Laboratories Co., Ltd.) according to the manufacturer's instructions. In brief, cells were cultured in 96-well plates in the medium of the different treatment groups for 24 h. Then, 10 µL of CCK-8 solution was added to each well and incubated for 1.5 hours. Finally, the absorbance was measured at 450 nm by using a microtitre plate reader.

**RNA isolation and Reverse transcription polymerase chain reaction (RT-PCR) analysis**

The total RNAs were extracted with TRIzol reagent following the manufacturer's instruction (Invitrogen, CA, USA) [19]. The cDNAs were prepared using SuperScript III reverse transcriptase and oligo primers (Thermo, Waltham, MA, USA) [28]. The *GAPDH* fragment was amplified as a reference gene. These primers for mouse gene were listed as follows:

Arg1: forward, 5'-CTCCAAGCCAAAGTCCTTAGAG-3' reverse, 5'-AGGAGCTGTCATTAGGGACATC-3'

CXCL10: forward, 5'-TCTGAGTGGGACTCAAGGGAT-3' reverse, 5'-TCGTGGCAATGATCTCAACACG-3'

GAPDH: forward, 5'-GGGTCCCAGCTTAGGTTCAT-3' reverse, 5'-CTCGTGGTTCACACCCATCA-3'

**Immunofluorescence staining**

Cells were fixed with 4% paraformaldehyde in PBS for 0.5 h, permeabilized with 0.5% Triton X-100 for 10 minutes and blocked in 5% normal goat serum in PBS for 1 h at room temperature. Next, cells were probed with anti-Nrf2 antibodies and Alexa Fluor 594-conjugated goat anti-rabbit IgG secondary antibody. After staining the cell nuclei with DAPI for 5 minutes, the immunofluorescent images were captured on a Zeiss fluorescence microscopy (Jena, Germany).

**Western blot assay**

Western blot analysis was performed as previously described [21]. Here, cells were collected, normalized and separated by 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (EMD Millipore). After 1 h of blocking with 5% non-fat milk in 1xTBST at room temperature, the membranes were incubated with primary antibodies (1:500-1:1000) overnight at 4°C and then were incubated with secondary antibody (1:5000) for 1 h at room temperature. Eventually, the membranes were washed three times with 1xTBST and detected by enhanced chemiluminescence (ECL) system (Amersham Bioscience). Densitometric analysis of Western blot was determined with VisionWorks LS, version 6.7.1.

**Statistics analysis**
Data analysis was performed using GraphPad Prism 5.0 (San Diego, CA, USA). All data in our study are presented as the mean ± SEM. Shapiro-Wilk normality test was performed to evaluate the normality of the data distribution. Comparisons of parameters among three or more groups were performed with a one-way analysis of variance (ANOVA). Differences between 2 groups were compared by using Student’s \( t \) test. The Bonferroni testing was performed to determine the post hoc testing. \( P \) value \(< 0.05 \) were considered statistically significant.

Results

**Intramyocardial injection of Exosomes derived from FNDC5-MSCs significantly attenuated cardiomyocyte apoptosis in MI mice**

Exosomes were isolated by density-gradient ultracentrifugation. As shown in Supplemental Fig. 1A, 1B, exosomes showed a cup-shaped morphology by TEM, and the size of exosomes was about 100 nm by NTA. Meanwhile, markers of exosomes (CD63, CD81 and ALIX) were highly expressed in FNDC5-MSCs-Exo groups compared with MSCs-Exo group (Supplemental Fig. 1C). 50 µg MSCs-Exo or FNDC5-MSCs-Exo dissolved in 50 µL PBS was injected into the infarct border zone at four spots. (Fig. 1A).

TUNEL assay was used to detect the cardiomyocyte apoptosis after MI. As shown in Fig. 1B, TUNEL-positive (green) cardiomyocytes in MSCs-Exo and FNDC5-MSCs-Exo group were decreased compared with PBS group. Meanwhile, the quantitative analysis reveals that the percentages of TUNEL-positive cells exposed to MSCs-Exo, and FNDC5-MSCs-Exo group were 11.37 ± 0.59% and 6.97 ± 0.46% respectively, significantly decreased as opposed to the PBS group (13.5 ± 0.43%, \( p < 0.05 \)). What is more, compared with MSCs-Exo group, the apoptosis rate of cells was remarkably decreased in FNDC5-MSCs-Exo group (\( P < 0.05 \)). Western blot analysis further confirmed that the cardioprotective effect of MSCs-Exo and FNDC5-MSCs-Exo with reducing protein amounts of Bax and cleaved caspase-3 in ischemic heart tissue (Fig. 1C and 1D, \( P < 0.05 \)). Taken together, FNDC5-MSCs-Exo could attenuate cardiomyocyte apoptosis after MI.

**FNDC5-MSCs-Exo administration reduced post-infarction inflammation and increased M2 macrophage polarization in vivo**

MI injury induced post-infarction inflammation, and a great amount of inflammatory cells assembled and infiltrated into the infarction area. H&E staining showed that in both MSCs-Exo and FNDC5-MSCs-Exo group, FNDC5-MSCs-Exo obviously alleviated the infiltration of inflammatory cells to protect myocardium from further damage (Fig. 2A). Furthermore, the pro-inflammatory cytokines, TNF-α and IL-6, were detected in serum at 3 and 7 days. Compared with MSCs-Exo group, the secretions of TNF-α and IL-6 were significantly reduced in FNDC5-MSCs-Exo group (Fig. 2B-E, \( P < 0.05 \)).
Macrophage polarization played an essential role in inflammation. Thus, we explored the subsets of macrophages accumulating in the ischemic heart. Western blot analysis verified that the protein expression of CD206 (M2 marker) in ischemic heart tissue was elevated under MSCs-Exo and FNDC5-MSCs-Exo group (Fig. 2F, 2G). Furthermore, FNDC5-MSCs-Exo presented better effects than MSCs-Exo on facilitating M2 macrophage polarization after MI (Fig. 2H and 2I, P < 0.05). Collectively, compared with MSCs-Exo, FNDC5-MSCs-Exo reduced post-infarction inflammation and promoted M2 macrophage polarization in mice.

**FNDC5-MSCs-Exo ameliorates inflammation responses by increasing anti-inflammatory cytokines, as well as decreasing pro-inflammatory cytokines in Raw264.7 cells**

To further investigate the effects of MSCs-Exo, FNDC5-MSCs-Exo on inflammation responses, exosomes were administrated to Raw264.7 cells under LPS treatment (100 ng/mL). To optimize the reasonable dose of exosomes, we detected the effects of different doses of exosomes (5, 10, 15 and 20 µg/mL) on inflammatory cytokines. ELISA analysis showed that the pro-inflammatory cytokines (IL-6, TNF-α and IL-1β) were decreased while the anti-inflammatory cytokine (IL-10) was increased in both Exo and L-Exo groups by a dose-dependent manner (Fig. 3A-D, P < 0.05). Moreover, the pro-inflammatory cytokines were dramatically decreased by exosomes at 20 µg/mL (P < 0.05). Thus, the dose of exosomes was performed to further study.

CCK-8 assay was performed to confirm that MSCs-Exo and FNDC5-MSCs-Exo reduced pro-inflammatory cytokines without affecting cell viability. Data showed no significant influence on cell viability (Supplemental Fig. 2).

In summary, our data indicated that FNDC5-MSCs-Exo had superior therapeutic effects on anti-inflammation by increasing anti-inflammatory cytokines and decreasing pro-inflammatory cytokines.

**FNDC5-MSCs-Exo dramatically increased M2 macrophage polarization and decrease M1 macrophage polarization in vitro**

To explore macrophage polarization, we detected macrophages markers CD11b, CXCL10 (M1 macrophages) and CD206, ArgI (M2 macrophages). Western blot analysis indicated that MSCs-Exo, FNDC5-MSCs-Exo significantly increased the expression level of CD206, while markedly reduced the expression level of CD11b compared with LPS group (Fig. 4A-C, P < .05). Furthermore, the RT-qPCR results showed that the mRNA level of CXCL10 remarkably reduced and Arg1 was significantly elevated in FNDC5-MSCs-Exo group (Fig. 4D-4E, P < 0.05).

Taken together, these results showed that FNDC5-MSCs-Exo markedly promoted M2 macrophage polarization while reduced M1 macrophage polarization.

**FNDC5-MSCs-Exo reduced the inflammation by suppressing the NF-κB signaling pathway and upregulating Nrf2/HO-1**
Axis

To further understand the molecular mechanism of inflammation regulated by exosomes, we evaluated the effects of MSCs-Exo and FNDC5-MSCs-Exo on LPS-dependent NF-κB signaling pathway. The Western blot results showed that compared with LPS group, total protein of IkBα was increased while p-IkBα was decreased in both MSCs-Exo and FNDC5-MSCs-Exo group (Fig. 5A-5C, P < 0.05). Furthermore, NF-κB p65 translocation from the cytoplasm to nucleus was suppressed (Fig. 5D-5E, P < 0.05). We also found that compared with MSCs-Exo group, FNDC5-MSCs-Exo prominently suppressed the nuclear translocation of NF-κB p65 (Fig. 5F-5G, P < 0.05). Meanwhile, we focused on the effects of MSCs-Exo and FNDC5-MSCs-Exo on the Nrf2/HO-1 pathway by immunostaining and Western blot analysis. As indicated in Fig. 6A, FNDC5-MSCs-Exo obviously induced the nuclear translocation of Nrf2. Then, Western blot analysis also suggested that FNDC5-MSCs-Exo increased HO-1 expression (Fig. 6B-6C, P < 0.05).

To clarify the impact of HO-1 on the anti-inflammatory activities of FNDC5-MSCs-Exo, HO-1 specific inhibitor Sn (IV) protoporphyrin IX dichloride (SnPP, 20 µM) was administrated to block the enzyme activity of HO-1. As shown in Fig. 6D and 6E, SnPP attenuated the inhibitory effect of FNDC5-MSCs-Exo on nucleus translocation of NF-κB p65 (P < 0.05). ELISA analysis suggested that HO-1 inhibitor dramatically recovered secretion of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β (Fig. 6F-6H, P < 0.05). Furthermore, the RT-qPCR results showed that HO-1 inhibitor significantly elevated the mRNA level of CXCL10 while reduced that of Arg1 compared with FNDC5-MSCs-Exo group (Fig. 6I-6J, P < 0.05).

Discussion

Our previous study found that FNDC5 pre-treatment improved BMMSCs therapy effect for MI [21]. Interestingly, we also found that FNDC5-optimized BMMSCs secreted more exosomes. However, its role in post-infarction inflammation remains unclear. Therefore, the present study aimed to evaluate the effect of exosomes derived from optimized BMMSCs on inflammation after MI injury. Here, our study led to two key findings as follows: 1) FNDC5-MSCs-Exo had superior therapeutic effects on anti-inflammatory and anti-apoptosis, as well as polarizing M2 macrophage. 2) FNDC5-MSCs–Exo decreased the secretion of pro-inflammatory cytokines in macrophage, while increased the anti-inflammatory cytokine under LPS stimulation. Collectively, our data suggested that FNDC5-MSCs–Exo may be an optimizing strategy of BMMSCs-based therapy for MI (Fig. 7).

Previous studies have shown that exosomes secreted by stem cells play multiple effects, including immune regulation, anti-inflammatory, anti-apoptosis, reducing fibrosis, inhibiting oxidative stress, and enhancing angiogenesis [12, 29], suggesting exosomes may be alternatives to cell therapy for MI. However, increasing studies have found that exosomes derived by usual stem cells have limitations to repair myocardial tissue, pre-treatment of stem cells can enhance their protective effect on ischemic myocardium [13–15]. In present study, we discovered that compared with MSCs-Exo, FNDC5-MSCs-Exo could significantly ameliorate post-infarction cardiomyocytes apoptosis, suggesting optimized stem cells can enhance the protective effects of exosomes on ischemic myocardium.
Inflammation responses have an essential effect during MI [30]. After MI, macrophages were recruited into the ischemic myocardial tissue and participate in inflammation responses and myocardial repair [31, 32], suggesting the key of post-infarction repair on anti-inflammation and remaining the balance of macrophage polarization. In present study, MSCs-Exo and FNDC5-MSCs-Exo reduced the infiltration of inflammatory cells, improved secretion of pro-inflammatory cytokines in the ischemic heart tissue. Meanwhile, we also found that FNDC5-MSCs-Exo had more effective influence on M2 macrophage polarization in vivo. To further investigate the effect of exosomes on inflammation, we co-cultured Raw264.7 cells with different exosomes after LPS treatment. Our data indicated that MSCs-Exo and FNDC5-MSCs-Exo increased anti-inflammatory cytokines (IL-10) and decreased pro-inflammatory cytokines (IL-6, TNF-α and IL-1β), as well as increased M2 macrophage marker Arg1, and decrease M1 macrophage marker CXCL10, suggesting MSCs-Exo and FNDC5-MSCs-Exo promoted M2 macrophage polarization while suppressed M1 macrophage polarization.

To elucidate the underlying mechanisms, we firstly investigated the effects of MSCs-Exo and FNDC5-MSCs-Exo on the nuclear translocation of NF-kB. As we known, LPS stimuli are known to activate the NF-κB pathway for regulating the expression of immunomodulating and inflammatory genes [33]. NF-κB activation is a complex process involving rapid phosphorylation and degradation of IκB. Ultimately, NF-κB p65 subunits are translocated to the cell nucleus and induce IL-6 and TNF-α [34]. Here, Western blotting analysis showed that MSCs-Exo and FNDC5-MSCs-Exo reduced the nuclear translocation of NF-kB in RAW264.7 cells after LPS stimulation. These results suggested that inhibition of NF-κB pathway is the mechanisms by which MSCs-Exo and FNDC5-MSCs-Exo selectively suppresses the expression of pro-inflammatory cytokines. Nrf2 is a transcriptional factor and regulates the cellular defense against oxidative stress [35]. Some anti-inflammatory factors disrupt Keap1-Nrf2 complex, promote the nuclear translocation of Nrf2 and finally activate the transcription of antioxidant genes, such as heme oxygenase-1 (HO-1) [36]. HO-1 is well-known to orchestrate the cross-talks between Nrf2 and NF-kB pathways [37]. Therefore, to further elucidate the underlying mechanisms, we focused on the Nrf2/HO-1 pathway. In the present study, we found that FNDC5-MSCs-Exo strongly induced the nuclear translocation of Nrf2 and increased expression of HO-1 protein. Thus, we hypothesized that FNDC5-MSCs-Exo might regulate inflammation responses and macrophage M2 polarization via activating Nrf2/HO-1 pathway. We further gave cells treatments of HO-1 inhibitor SnPP. Surprisingly, SnPP diminished the inhibitory effect of FNDC5-MSCs-Exo on NF-κB activation and reducing secretion of pro-inflammatory cytokines in macrophages. Meanwhile, SnPP reversed the effect of FNDC5-MSCs-Exo on downregulation of M1 macrophage polarization and upregulation of M2 macrophage polarization. These results suggested that FNDC5-MSCs-Exo activated Nrf2/HO-1 which was the key mechanism for inhibiting NF-κB pathway and subsequently down-regulating LPS-induced inflammation responses.

The present study bears some clinical relevance, but there are limitations. Firstly, we did not follow up MI mice for longer time to observe the changes in cardiac function. Secondly, the detailed molecular mechanism by which exosomes exerted protective effects on inflammation was not clarified completely. Therefore, further research needs to be conducted.
Conclusions

Thus, our study in vitro and in vivo showed that FNDC5-MSCs-Exo had superior therapeutic effects on anti-inflammation and polarizing M2 macrophage, which partly depressed NF-κB pathway and upregulated Nrf2/HO-1 Axis. These findings suggested that exosomes from optimized BMMSCs may be a potential target for MI.

Abbreviations

FNDC5: Fibronectin type III domain-containing protein 5; BMMSCs: Bone marrow mesenchymal stem cells; MI: Myocardial infarction; DMEM: Dulbecco’s modified Eagle’s medium; FBS: Fetal bovine serum; ELISA: Enzyme-linked immunosorbent assay; LAD: Left anterior descending; LV: Left ventricle; ECG: Electrocardiography; TUNEL: Terminal-deoxynucleotidyl transferase mediated-dUTP nick-end labeling; DAPI: 4,6-diamidino-2-phenylindole; PBS: Phosphate-buffered saline; NTA: Nanoparticle tracking analysis; TEM: Transmission electron microscope; CCK-8: Cell Counting Kit-8; TNF-α: Tumour necrosis factor-α; IL-6: Interleukin; IL-1β: interleukin 1β; IL-10: interleukin; Arg 1: Arginase I; HO-1: Heme oxygenase-1

Declarations

Funding

This work was supported by the National Key Research and Development Program of China (2017YFC0908402) and Military Medical Science and Technology Youth Training Program (17QNP029).

Availability of data and materials

The data sets supporting the results of this article are included within the article and its additional files.

Authors’ contributions

HJN, HXC, YC and ZZ designed the study, drafted the manuscript, approved its final version and acquired data. JYD, CX and LNS revised the article’s intellectual content. CY, ZZ are responsible for the integrity of this work. All authors read and approved the final manuscript.

Ethics approval

All procedures were performed in accordance with the institutional guidelines for animal research and were approved by the Animal Care and Use Committee of PLA Rocket Force Characteristic Medical Center.

Consent for publication

Not applicable.

Availability of data and materials
The data sets supporting the results of this article are included within the article and its additional files.

**Competing interests**

All the authors declare that they have no competing interests.

**Acknowledgements**

Not applicable.

**Authors’ information**

1 The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.

2 The Second Medical Center, Chinese PLA General Hospital, Beijing, 100853, China

3 Air Force Military Medical University, Xi’an, Shaanxi, 710032, China.

4 PLA Rocket Force Characteristic Medical Center, Beijing 100088, China.

**References**

1. Anzai T. Post-infarction inflammation and left ventricular remodeling. Circ J. 2013;77:580–7.

2. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int J Cardiol. 2008;130:147–58.

3. Abumaree MH, Al Jumah MA, Kalionis B, et al. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rev. 2013;9:620–41.

4. Perego C, Fumagalli S, Zanier ER, et al. Macrophages are essential for maintaining a M2 protective response early after ischemic brain injury. Neurobiol Dis. 2016;96:284–93.

5. Ben-Mordechai T, Palevski D, Glucksam-Galnoy Y, Elron-Gross I, Margalit R, Leor J. Targeting macrophage subsets for infarct repair. J Cardiovasc Pharmacol Ther. 2015;20:36–51.

6. Karantalis V, DiFede DL, Gerstenblith G, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: the Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res. 2014;114:1302–10.

7. Vagnozzi RJ, Maillet M, Sargent MA, et al. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature. 2020;577:405–9.

8. Hu M, Guo G, Huang Q, et al. The harsh microenvironment in infarcted heart accelerates transplanted bone marrow mesenchymal stem cells injury: the role of injured cardiomyocytes-derived exosomes. Cell Death Dis. 2018;9:357.
9. Huang Q, Cai B. Exosomes as New Intercellular Mediators in Development and Therapeutics of Cardiomyocyte Hypertrophy. Adv Exp Med Biol. 2017;998:91–100.

10. van der Pol E, Coumans FA, Grootemaat AE, et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost. 2014;12:1182–92.

11. Michiel Pegtel D, Stephen J, Gould. Exosomes. Annu Rev Biochem. 2019;88(1):487–514.

12. Moghaddam AS, Afshari JT, Esmaeili S-A, et al. Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease. Atherosclerosis. 2019;285:1–9.

13. Xu R, Zhang F, Chai R, et al. Exosomes derived from pro-inflammatory bone marrow-derived mesenchymal stem cells reduce inflammation and myocardial injury via mediating macrophage polarization. J Cell Mol Med. 2019;23:7617–31.

14. Peisen Huang L, Wang X, Tian, et al. Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19. Cardiovasc Res. 2020;116:353–67.

15. Rossana Domenis A, Cifù S, Quaglia, et al. Proinflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes. Sci Rep. 2018;8:13325.

16. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324–37.

17. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–8.

18. Lin C, Guo Y, Xia Y, et al. FNDC5/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin αV/β5-AKT signaling and reduction of oxidative/nitrosative stress. J Mol Cell Cardiol. 2021;160:27–41.

19. Deng J, Zhang N, Chen F, et al. Irisin ameliorates high glucose-induced cardiomyocytes injury via AMPK/mTOR signal pathway. Cell Biol Int. 2020;44(11):2315–25.

20. Panati K, Suneetha Y, Narala VR. Irisin/FNDC5—An updated review. Eur Rev Med Pharmacol Sci. 2016;20(4):689–97.

21. Deng J, Zhang N, Wang Y, et al. FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarction. Stem Cell Res Ther. 2020;11(1):228.

22. Deng J, Yang C, Wang Y, et al. Inositol pyrophosphates mediated the apoptosis induced by hypoxic injury in bone marrow-derived mesenchymal stem cells by autophagy. Stem Cell Res Ther. 2019;10:159.

23. Fan B, Li C, Szalad A, et al. Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes. Diabetologia. 2020;63(2):431–43.

24. Huan Liu S, Liu X, Qiu, et al. Donor MSCs release apoptotic bodies to improve myocardial infarction via autophagy regulation in recipient cells. Autophagy. 2020;29:1–16.
25. Ju C, Shen Y, Ma G, et al. Transplantation of cardiac mesenchymal stem cell-derived exosomes promotes repair in ischemic myocardium. Cardiovasc Transl Res. 2018;11(5):420–8.
26. Hu M, Zhang Z, Liu B, et al. Deubiquitinase inhibitor Auranofin attenuated cardiac hypertrophy by blocking NF-kappaB activation. Cell Physiol Biochem. 2018;45:2421–30.
27. Song Y, Dou H, Li X, et al. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1beta-primed mesenchymal stem cells against sepsis. Stem Cells. 2017;35:1208–21.
28. Cheng Y, Zhao J, Tse HF, Le XC, Rong J. Plant Natural Products Calycosin and Gallic Acid Synergistically Attenuate Neutrophil Infiltration and Subsequent Injury in Isoproterenol-Induced Myocardial Infarction: A Possible Role for Leukotriene B4 12-Hydroxydehydrogenase? Oxid Med Cell Longev. 2015;2015:434052.
29. Zhao J, Li X, Hu J, et al. Mesenchymal stromal cell-derived exosomes attenuate myocardial ischemia-reperfusion injury through miR-182-regulated macrophage polarization. Cardiovasc Res. 2019;115:1205–16.
30. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–35.
31. van Amerongen MJ, Harmsen MC, van Rooijen N, et al. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathology. 2007;170:818–29.
32. de Couto G, Gallet R, Cambier L, et al. Exosomal MicroRNA transfer into macrophages mediates cellular postconditioning. Circulation. 2017;136:200–14.
33. Liou HC. Regulation of the immune system by NF-kappa B and I kappa B. J Biochem Mol Biol. 2002;35:537–46.
34. Jiang K, Yang J, Xue G, et al. Fisetin Ameliorates the Inflammation and Oxidative Stress in Lipopolysaccharide-Induced Endometritis. J Inflamm Res. 2021;14:2963–78.
35. Arbab AAI, Lu X, Abdalla IM, et al. Metformin Inhibits Lipoteichoic Acid-Induced Oxidative Stress and Inflammation Through AMPK/NRF2/NF-κB Signaling Pathway in Bovine Mammary Epithelial Cells. Front Vet Sci. 2021;8:661380.
36. Agnieszka Loboda M, Damulewicz E, Pyza, et al. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci. 2016;73(17):3221–47.
37. Koliaraki V, Kollias G. A new role for myeloid HO-1 in the innate to adaptive crosstalk and immune homeostasis. Adv Exp Med Biol. 2011;780:101–11.

Figures
Figure 1

Intramyocardial spots injection of Exosomes derived from FNDC5-MSCs significantly suppressed cardiomyocyte apoptosis in MI mice. A The diagrammatic sketch of MI induction and exosome intramyocardial injection and mice were killed at 3 and 7 days after intramyocardial injection (n ≥ 14). B The apoptosis of cardiomyocytes at 7 days was assessed by a TUNEL Assay Kit (scale bars =20 μm). Nucleus was blue with DAPI and the TUNEL-positive apoptotic cardiomyocytes were green. The average
fluorescence intensity of positive apoptotic cardiomyocytes was quantified. The protein of Bax and cleaved caspase-3 within the heart tissue at 3 days (C) and 7 days (D) was detected by Western blot and Semi-quantification analysis. Data are expressed as the means ± SEM; n = 5; *P < 0.05.

Figure 2

FNDC5-MSCs-Exo administration reduced post-infarction inflammation and increased M2 macrophage polarization in vivo. A Representative images of inflammatory cells infiltration within the infarct border zone at 3 and 7 days were illustrated by H&E staining. Serum inflammatory cytokines (TNF-α and IL-6) at 3 days (B, C) and 7 days (D, E) were assayed by ELISA. Western blot analysis of CD206 protein at 3 days (F) and 7 days (G). Representative semi-quantification analysis of CD206 at 3 days (H) and 7 days (I). Data are expressed as the means ± SEM; n = 5; *P < 0.05.
Figure 3

FNDC5-MSCs-Exo ameliorates inflammation responses by increasing anti-inflammatory cytokines, as well as decreasing pro-inflammatory cytokines in Raw264.7 cells. The secretions of pro-inflammatory cytokines such as TNF-α (A), IL-6 (B) and IL-1β (C) and anti-inflammatory cytokine such as IL-10 (D) secreted from Raw264.7 cells were detected by ELISA. Data are expressed as the means ± SEM; n = 5; *P < 0.05 vs control group; # P < 0.05 vs LPS group; ^P < 0.05 vs MSCs-Exo group under equal concentration.
Figure 4

FNDC5-MSCs-Exo dramatically increased M2 macrophage polarization and decrease M1 macrophage polarization in vitro. A Western blot analysis of CD206 and CD11b in RAW264.7 cells with different treatments. Representative semi-quantification analysis of CD206 (B) and CD11b (C). Representative relative mRNA level of CXCL10 (D) and Arg 1(E). Data are expressed as the means ± SEM; n = 5; *P < 0.05.
Figure 5

FNDC5-MSCs-Exo reduced the inflammation by suppressing the NF-κB signaling pathway. A Representative Western blot analysis of p-IκBα and IκBα in RAW264.7 cells under different conditions. Representative semi-quantification analysis of p-IκBα (B) and IκBα (C). D Cytoplasmic and nuclear proteins were collected and extracted to measure IκBα and NF-κB p65. GAPDH (E, F) and Histone3 (G) were used as normalized cytoplasmic and nuclear protein. Data are expressed as the means ± SEM; n = 5; *P < 0.05.
Figure 6

FNDC5-MSCs-Exo reduced the inflammation by upregulating Nrf2/HO-1 Axis. A Representative Immunostaining of intracellular Nrf2 (scale bars =20 μm). After 24 h treatment with LPS, the intracellular Nrf2 was detected by immunostaining with specific antibody, whereas the nuclei were detected by DAPI staining. B Western blot analysis of HO-1 under different conditions. C Representative semi-quantification analysis of HO-1. D Nuclear proteins were collected and extracted to measure NF-κB p65. E Histone3 were
used as normalized cytoplasmic and nuclear protein. The secretions of TNF-α (F), IL-6 (G) and IL-1β (H) were detected by ELISA. Representative relative mRNA level of CXCL10 (I) and Arg 1 (J). Data are expressed as the means ± SEM; n = 5; *P < 0.05.

**Figure 7**

Proposed mechanism of FNDC5-MSCs-Exo improve myocardial injury. FNDC5-MSCs-Exo reduces inflammation and promotes M2 macrophage polarization via down-regulating NF-κB signaling pathway and up-regulating Nrf2/HO-1 Axis.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementalfigure1.tif
- Supplementalfigure2.tif